Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults

NCT04783311 is registered in ClinicalTrials.gov with EuBiologics Co.,Ltd as lead sponsor.

NCT NCT04783311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04783311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose-exploration, Randomized, Observer-blind, Placebo-controlled Study to Determine Safety, Tolerance and Immunogenicity of EuCorVac-19, a Recombinant Protein Vaccine, for the Prevention of COVID-19 in Healthy Adults
Lead sponsor
EuBiologics Co.,Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
February 23, 2021
Completion date
September 27, 2022
Enrollment
279 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19